BDBM101139 US10189794, Compound I-117::US10618902, Compound I-117::US10774052, Compound I-117::US9695132, I-117

SMILES COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4cn(C)nc4NC(=O)C=C)nc3N(C)C2=O)c1Cl

InChI Key InChIKey=FFIJDYFBAKJUNV-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 101139   

TargetFibroblast growth factor receptor 4(Human)
Celgene Car

US Patent
LigandPNGBDBM101139(US10189794, Compound I-117 | US10618902, Compound ...)
Affinity DataIC50: <100nMpH: 7.5Assay Description:Omnia Assay Protocol for Potency Assessment Against FGFR 4 Enzyme. a) [FGFR4-WT]=10 nM, [ATP]=300 uM, [Y10-Sox]=10 uM (ATP KMapp 300 uM): A 10x stock...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetFibroblast growth factor receptor 4(Human)
Celgene Car

US Patent
LigandPNGBDBM101139(US10189794, Compound I-117 | US10618902, Compound ...)
Affinity DataIC50: <100nMAssay Description:For MDA-MB-453 cells signaling, cells were grown in 96-well poly-D-lysine plates (BD Bioscience, San Jose, Calif.) to 90% confluence, and were then i...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetFibroblast growth factor receptor 4(Human)
Celgene Car

US Patent
LigandPNGBDBM101139(US10189794, Compound I-117 | US10618902, Compound ...)
Affinity DataIC50: <500nMAssay Description:A 10× stock solution of FGFR4-WT (PR4380C or P3054), (from Invitrogen, Carlsbad, Calif.) corresponding to method a in Table 10, was prepared as descr...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetFibroblast growth factor receptor 4(Human)
Celgene Car

US Patent
LigandPNGBDBM101139(US10189794, Compound I-117 | US10618902, Compound ...)
Affinity DataIC50: <100nMAssay Description:A 10× stock solution of FGFR4-WT (PR4380C), (from Invitrogen, Carlsbad, Calif.) corresponding to method a in Table 7, was prepared as described below...More data for this Ligand-Target Pair
In DepthDetails US Patent